Iwamoto Hiroaki, Izumi Kouji, Shimura Yusuke, Natsagdorj Ariunbold, Maolake Aerken, Takezawa Yuta, Nohara Takahiro, Shigehara Kazuyoshi, Kadono Yoshifumi, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Anticancer Res. 2016 Oct;36(10):5557-5561. doi: 10.21873/anticanres.11140.
Metastatic urothelial carcinoma is one of the most fatal urological malignancies. Cisplatin-based systemic chemotherapy is the standard treatment for metastatic urothelial carcinoma, and there is little evidence to support metastasectomy. The aims of the study were to evaluate the efficacy of metastasectomy and to investigate the prognoses of the patients. The study included 436 patients with urothelial carcinoma who were treated at our hospital. Of these, we included and retrospectively analyzed 29 patients who received curative treatment for the primary tumor and had been treated for metastases. Seven of these patients underwent metastasectomy. In a multivariate analysis, a serum C-reactive protein level before treatment for metastasis of <1 mg/dl and metastasectomy were independent significant predictors of both better progression-free survival and better overall survival. Metastasectomy may be considered a potential treatment for patients with metastases from urothelial carcinoma.
转移性尿路上皮癌是最致命的泌尿系统恶性肿瘤之一。以顺铂为基础的全身化疗是转移性尿路上皮癌的标准治疗方法，几乎没有证据支持进行转移灶切除术。本研究的目的是评估转移灶切除术的疗效并调查患者的预后。该研究纳入了在我院接受治疗的436例尿路上皮癌患者。其中，我们纳入并回顾性分析了29例接受了原发性肿瘤根治性治疗且已接受转移灶治疗的患者。这些患者中有7例接受了转移灶切除术。在多变量分析中，转移灶治疗前血清C反应蛋白水平<1 mg/dl和转移灶切除术是无进展生存期和总生存期改善的独立显著预测因素。对于尿路上皮癌转移患者，转移灶切除术可被视为一种潜在的治疗方法。
